DUBLIN, Jan. 30, 2018 /PRNewswire/ --

The "Bipolar Disorder Market Analysis By Drug Class (Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety), By Mechanism of Action, By Region, And Segment Forecasts, 2014 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global bipolar disorder market is anticipated to reach USD 4.9 billion by 2025, growing at a CAGR of 2.10%

Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient's mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation's Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient's mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period.

Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Further Key Findings From the Study Suggest:

• The antipsychotic segment is expected to dominate the market owing to increasing prevalence of psychosis, and physical illness resulting in depression.
• The serotonin norepinephrine reuptake inhibitor segment is anticipated to dominate the market in the forecast period. The growth of this segment is due to these drugs being primarily used to treat major depression and bipolar disorder, and having better safety profile and tolerability.
• North America is expected to dominate global bipolar disorder market. This can be attributed to the high stress levels, insufficient sleep, and trend of substance abuse amongst the population.
• Some of the major players in this space include GlaxoSmithKline (GSK), Pfizer Inc., Janssen Pharmaceuticals, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc., Otsuka Holdings Co. Ltd, and AstraZeneca.

Key Topics Covered:

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Bipolar disorder Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of bipolar disorder
3.1.1.2 Increasing government support
3.1.1.3 Technological advancements
3.1.2 Market restraint analysis
3.1.2.1 Side effects associated with bipolar drugs
3.1.2.2 Misdiagnosis of bipolar disorder
3.2 Penetration & Growth Prospect Mapping
3.3 SWOT Analysis, By Factor (political & legal, economic, and technological)
3.3.1 Market SWOT Analysis, By Factor (political & legal, economic, and technological)
3.4 Industry Analysis - Porter's
3.4.1 Porter's Five Forces analysis

Chapter 4 Bipolar disorder Drug Class Estimates & Trend Analysis
4.1 Bipolar disorder Market: Drug Class Movement Analysis
4.2 Mood stabilizer
4.3 Anticonvulsants
4.4 Antipsychotic drugs
4.5 Antidepressant drugs
4.6 Antianxiety drugs

Chapter 5 Bipolar disorder Mechanism of Action Estimates & Trend Analysis
5.1 Bipolar disorder Market: Mechanism of Action Movement Analysis
5.2 Selective serotonin reuptake inhibitor
5.3 Serotonin norepinephrine reuptake inhibitor
5.4 Tricyclic antidepressants
5.5 Monoamine oxidase inhibitor
5.6 Benzodiazepines
5.7 Benzodiazepines
5.8 Others

Chapter 6 Bipolar disorder Regional Estimates & Trend Analysis, by Drug Class, and Mechanism of Action

Chapter 7 Competitive Landscape

• GlaxoSmithKline
• Pfizer Inc.
• Janssen Pharmaceuticals
• Eli Lily
• Allergan Plc.
• Norvartis
• AbbVie Inc.
• Otsuka Holdings Co.Ltd
• AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/research/cnftlg/bipolar_disorder?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets